预约演示

AstraZeneca and Merck's Lynparza set to 'dominate' PARP market as it looks to grow cancer offerings with 100-plus ongoing trials

2024-04-24

上市批准并购临床3期临床1期临床结果

AstraZeneca also has a new PARP inhibitor in early trials that could help boost future lagging sales from Lynparza when it starts to lose patent protection in 2028.

AstraZeneca and Merck & Co.PARPe the first to grab an FDA approval for their PARP inhibitor Lynparza, and,Lynparza growing competition, the drug is set to remain top dog in the PARP space.

AstraZenecardingMerck & Co.eport out by analysts at GlFDAlData, which predictPARP billion inLynparzasales for Lynparza by 2027, boosted by new licenses.PARP

Lynparza (olaparib) was first approved for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer Lynparza who had already been given three lines or more of chemo back in 2014.

Lynparza (olaparib)racked up supplemental U.S. nodbreast cancer gene (BRCA)-mutated metastatic ovarian cancer, pancreatic and ovarian tumors.

GlobalData sees the drug’s revenues in these indications to reacancersr 68% of the global PARP inhibitors market by 2027,” helping bring in that $4 billion. Most of Lynparza's sales come from ovarian and HER2-negative breast cancer treatment, the analysts said in their latest report.

It doesn’t have the market to itself, however, with GSK’s PARP inhibitor Zejula (niraparibPARP inhibitors PARPlding the second position, with more than $1.6 billion in sales and 28%Lynparzamarket share.ovarian and HER2-negative breast cancer

The drug, which was originally developed by Tesaro bGSKre PARP inhibitor Zejula PARPg bought out by GSKniraparib first approval in 2017 for ovarian cancer. It has since added several new licenses within that disease space.

It’s not all been positive for Lynparza and Tesaro however. AZ and Merck back GSKthe fall of 2022 voluntarily pulled tovarian cancerreating heavily pretreated ovarian cancer patients, after seeing a potential “detrimental effect” on patient survival from a confirmatory phase 3 trial.

GSK and Clovis Oncology, for itLynparzaubraca, had also pulled theiMerckgs in the same patient population. Rubraca has seen the hardest path, with Clovis a yeaovarian cancer off the PARP drug in a bankruptcy sale to a Swiss pharma. The drug never really picked up after its approval in 2016 and has been the weak link in the PARP market.

GSK LynpClovis Oncology, however, the Rubracawals did not cause much of a sales impact, given that the drugs have largely moved into earlier treatmClovisttings.PARP drug PARP

And,LynparzaynparZejulal be making strong blockbuster sales in 2027, patent protection in the U.S. falls off in 2028. From then on, “there is an anticipated downshift in sales post-patent expiry through generic erosion,” said Biswajit Podder, Ph.D., oncology and hematology analyst at GlobalData.

But there iLynparzan the horizon. Lynparza currently has 123 ongoing phase clinical trials across a multitude of cancer types and combos, which GlobalData says “signifies its pivotal role in oncology.”oncology

AZ is also working on an experimenLynparzactive PARP1 inhibitor, saruparib, which has shown some early promise incancer 1/2 trials for homologous recombination repair (HRR)-deficient advancedoncologycancers.

“If approved, saruparib would further strengthenPARP1 inhibitor PARP1aZeneca’s lesaruparib PARP inhibitor market,” Podder said.(HRR)-deficient advanced breast cancers

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构